by Admin | Oct 13, 2021 | Senza categoria
https://medcitynews.com/ Takeda Pharmaceutical is collaborating with Poseida Therapeutics in an effort to provide a safer alternative for the development of gene therapies through non-viral technologies. In fact, currently, one of the obstacles in the advancement of...
by Admin | Oct 8, 2021 | Senza categoria
https://ir.selectabio.com/ Selecta Biosciences announced that it has entered into a strategic licensing agreement with Takeda Pharmaceutical Company Limited to develop next-generation gene therapies for two indications in the field of lysosomal storage diseases....
by Admin | Oct 1, 2021 | Senza categoria
https://www.kitepharma.com/ Kite Pharma, a GILEAD company, has announced that the FDA has approved TECARTUS® (brexucabtagene autoleucel) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia...
by Admin | Sep 20, 2021 | Senza categoria
Aggiornamento del Report tecnico-scientifico AIFA su KYMRIAH AIFA has released the update of the technical-scientific report regarding KIMRIAH® (tisagenlecleucel) by Novartis. KIMRIAH® is indicated for the treatment of paediatric and young adult patients up to and...
by Admin | Sep 13, 2021 | Senza categoria
https://news.abbvie.com/ Abbvie e REGENXBIO announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal...
